Abstract Published systematic reviews concluded that there is moderate to strong evidence to infer a potential role of lead and cadmium, widespread environmental metals, as cardiovascular risk factors. For other non-essential metals, the evidence has not been appraised systematically. Our objective was to systematically review epidemiologic studies on the association between cardiovascular disease in adults and the environmental metals antimony, barium, chromium, nickel, tungsten, uranium, and vanadium. We identified a total of 4 articles on antimony, 1 on barium, 5 on chromium, 1 on nickel, 4 on tungsten, 1 on uranium, and 0 on vanadium. We concluded that the current evidence is not sufficient to inform on the cardiovascular role of these metals because of the small number of studies. Few experimental studies have also evaluated the role of these metals in cardiovascular outcomes. Additional epidemiologic and experimental studies, including prospective cohort studies, are needed to understand the role of metals, including exposure to metal mixtures, in cardiovascular disease development.
Introduction
Substantial epidemiologic and experimental evidence supports the role of lead and cadmium, widespread environmental metals, in the development of cardiovascular disease of atherosclerotic origin. The epidemiologic evidence for those two metals has been summarized in recent systematic reviews [1, 2] . In animal studies, lead and cadmium induced aortic atherosclerosis [3, 4] . The potential cardiovascular effect of these divalent cations, moreover, has been reinforced with the finding that repeated edetate disodium chelation can prevent cardiovascular disease outcomes compared to placebo [2, 5••] , although other essential divalent cations may also be involved. Multiple metals can induce oxidative stress, a main proposed mechanism for their potential atherogenic effects [6, 7] . Specifically, metals can produce reactive radicals, deplete glutathione and other proteins with sulfhydryl groups, and bind enzymes involved in redox balance [1, 6] . Several metals can also disrupt endocrine and endothelial vascular functions [8] [9] [10] [11] . Recent epidemiologic and experimental evidence points to the possibility that environmental metals can interfere with enzymes involved in the one-carbon and citric acid metabolism and in histone modification pathways, resulting in anomalous DNA-methylation status throughout the genome and changes in gene expression [12] [13] [14] [15] . The potential atherogenicity of metals, thus, is likely not restricted to lead and cadmium.
While in humans the accumulated evidence strongly suggests a potential role of metals such as cadmium and lead in cardiovascular risk [1, 2] , for other non-essential metals, the evidence has not been systematically appraised. Most occupational studies, unfortunately, have been limited in their ability to inform the role of metals in cardiovascular disease due to the use of indirect measures of exposure instead of individual exposure assessment measures, such as biomarkers, potential residual confounding by not adjusting for cardiovascular risk factors and the healthy worker survivor effect bias, and potential co-exposures.
Our objective was to conduct a systematic review and synthesis of results from epidemiologic studies evaluating the association of biomarkers of exposure to environmental nonessential metals beyond lead and cadmium with cardiovascular disease of atherosclerotic origin. We did not include inorganic arsenic, a metalloid, nor mercury, a metal with a complex body of evidence on its relationship with cardiovascular disease, due to major confounding by seafood exposure [16] [17] [18] . For chromium, although there is some evidence that chromium III [Cr (III)] could be an essential element, this is not proven and chromium VI [Cr (VI)] on the other hand is an established toxic metal. Metals reviewed in this systematic review included antimony, barium, chromium, nickel, tungsten, uranium, and vanadium. In addition to the systematic review, for each metal we also provide a background on exposure sources, biomarker interpretation, and main health effects. We organized the presentation of the results by environmental metal. We also provide a summary table with the characteristics and the interpretation of most commonly used metal biomarkers (Table 1) .
Methods for the Systematic Review
Search strategy, study selection, and data abstraction We searched PubMed for relevant studies published through April 1, 2016 using the search strategy described in Supplemental File 1. The search strategy retrieved a total of 3445 citations (including duplicates). We included all articles assessing environmental metal exposure using biomarkers. The search had no language restrictions. Two investigators (A.E.N. and A.R.H.) independently reviewed each of all the abstracts and selected 57 references applying the following study exclusion criteria ( Fig. 1): (1) no original research (i.e., reviews, editorials, nonresearch letters), (2) no human study, (3) no atherosclerosis outcomes, (4) no environmental metal exposure levels measured in biological tissues (e.g., environmental measures such as water or air, or distance from a source, including radiation for uranium), and (5) case report or case series. For antimony, we identified two additional studies by manual search [33, 35••] . In this systematic review, the focus was on the role of environmental metal exposure in atherosclerotic cardiovascular disease in adults. Age, sex, and smoking are major determinants of metal levels in the human body and major risk factors for cardiovascular disease. We thus excluded, as a second layer of exclusion, 41 studies not adjusting for age, sex, or smoking . Any discrepancies were resolved by consensus, and if necessary, a third reviewer was involved. A native speaker reviewed the full text of any non-English article that could not be included or excluded based on the initial abstract review. We included in the final review ten papers, some of them measuring multiple environmental metals evaluated in unique study populations [31] [32] [33] [34] (Fig. 1) . Our review identified no publications investigating the association between vanadium and atherosclerotic disease. After retrieval of articles from the search, the reference lists of selected articles were checked for other potentially relevant articles, identifying no additional studies.
To assess study quality, we adapted the criteria used by Longnecker et al. [72] for observational studies (Supplemental File 2). We followed the criteria proposed by the 2004 US Surgeon General Report on the health consequences of smoking [73] , which include the evaluation of consistency, temporality, strength, dose-response relationship, and biological plausibility including confounding. As a result, the evidence for each environmental metal and atherosclerosis endpoint was classified in four groups as modified from the Surgeon General Report: sufficient evidence, suggestive but not sufficient evidence, insufficient evidence to infer a relationship, and suggestive of no relationship.
Statistical analysis
We collected the following data for each study: first author, year of publication, study design, size and population characteristics, exposure assessment and categories for comparison, endpoint ascertainment and endpoint definition, measures of association for a change in metal levels, and 95 % confidence interval or p values and adjustment factors. For some studies that reported only the association for metal categories, we reported the estimated relative risk (RR) comparing the highest to the lowest categories. For chromium only, a pooled RR estimate for CVD was calculated across five studies using an inverse-variance weighted random effects model in the meta package in Stata version 13.1 [74] . Pooled RR estimates for CVD were also calculated for each study that assessed multiple CVD outcomes. Pooled RRs are for descriptive purposes only and should be interpreted with caution, as there is substantial heterogeneity in the biomarker type, comparison unit, and CVD outcome definition across studies. Thus, the pooled RRs and confidence intervals must be taken with caution. While most studies reported cross-sectional odds ratios (ORs), we interpret the pooled estimates as RR estimates. However, several studies reported high prevalence of the outcome such that the OR may over-or underestimate the RR [75] .
Two study populations had information on both prevalent and incident CVD endpoints [35••, 76] . For these studies, we used incident outcomes only when pooling. We evaluated heterogeneity between studies using the I 2 statistic, which describes the total variability across all studies due to heterogeneity [77] . Additionally, we tested for influential studies by omitting each study sequentially and assessed publication bias using funnel plots.
Current Perspectives and Result Antimony
Antimony is naturally occurring in the Earth's crust and can also be released from anthropogenic sources, particularly coal and refuse combustion, and nonferrous metal mining, smelting, and refining [78] . The general population is exposed to antimony from food and water [79] , ambient air [78] , and through antimonial medicines [80] . Antimony is mainly excreted through urine and feces, with a half-life that varies by species, ranging from 24 h for Sb(V) to 94 h for Sb(III) [20] . In epidemiologic studies, antimony concentrations in urine reflect recent exposure [20] . Antimony at high exposure levels has been related to respiratory illness [81] , gastrointestinal effects [82] , dermatitis [83] , and cardiovascular effects such as altered electrocardiography readings and elevated blood pressure [80, 84] . Relatively little is known, however, about antimony toxicity and atherosclerosis. In an occupational study of Hispanic men employed at an antimony smelter in Texas, antimony exposure was not associated to cardiovascular mortality [85] . In the general population, antimony exposure has been associated with elevated blood pressure [86] and diabetes [87] . Fatal arrhythmias, QT prolongation after correcting for heart rate, and other electrocardiogram abnormalities are known, but uncommon, side effects of long-term antimonial medicine use [80, 88, 89] . In vitro evidence suggests that antimony exposure is associated with oxidative stress [20] and intracellular calcium dysregulation [90] in cardiac myocytes. In vivo evidence shows that antimony exposure is associated with elongated cardiac action potentials (53) and altered ECG readings and cardiomyopathy [91] . Antimony can also modify arsenic toxicity by altering arsenic metabolism, and co-exposure is likely as both metals occur together in the environment [20] .
In the systematic review, we identified four publications investigating the association between antimony and atherosclerotic disease that met the inclusion criteria (Table 2) [ 31-33, 35••] . These studies were all conducted in the general US population using the National Health and Nutrition Fig. 1 [32] General US population, NHANES 1999-2000 Examination Survey [31] [32] [33] 35 ••]. Antimony exposure was measured in urine only. Cardiovascular disease endpoints were based on examination (peripheral arterial disease) [32] , linkage to the National Death Index (heart disease mortality) [35••] and self-report (prevalence of combined cardiovascular disease [31] and specific endpoints such as coronary heart failure, coronary heart disease, heart attack, and stroke [33] ). Two studies reported dose-response associations of urinary antimony with prevalent endpoints using flexible splines [32, 35••] . Three studies took into account urine dilution by adjusting the regression models by urine creatinine. One study both adjusted models for creatinine and divided urinary antimony levels by creatinine, with sensitivity analyses showing an attenuation of effect estimates for heart disease mortality when only adjusting the regression model for creatinine [35••] . Effect estimates for prevalent self-reported atherosclerotic disease remained unchanged.
In general, studies mostly showed a trend toward an increased risk of atherosclerotic disease with increased antimony exposure, although only the associations with the prevalence of combined CVD [31] , peripheral arterial disease [32] , and self-reported congestive heart failure and heart attack [35••] were statistically significant. Confounding by other cardiovascular risk factors, including smoking, was generally addressed. Two studies reported adjustments for other heavy metals such as lead and cadmium [33, 35••] .
Chromium
Chromium is found in nature primarily as chromite ore. Chromium +3 (Cr (III)) and +6 (Cr (VI)) oxidation states are the most common in chromium compounds [92] . Cr(III) is the dominating species in the environment, but in some areas, the ground water can have an elevated content of Cr(VI) [93] . Chromium and its salts are used in metallurgical, refractory, and chemical industries. The essentiality of Cr(III) and the use of it as supplement for glycemic control in type 2 diabetes are controversial [94] . Several clinical trials have evaluated the effect of chromium supplementation on glycemic control, with inconsistent findings [95] [96] [97] [98] . Some studies have reported a potential role of Cr(III) in the maintenance of normal glucose tolerance through increasing the activity of insulinstimulated tyrosine kinase [99] . Alternatively, exposure to Cr(VI) compounds have shown associations with increased risk of dermatitis, ulcerative upper airway disease, kidney disease, and respiratory cancer [100] [101] [102] [103] .
Stainless steel welders are exposed to Cr(VI) through air [104, 105] in co-exposure with oxides of nickel and other metals (Mn, Fe, Al) [105] . Because Cr(VI) is rapidly reduced to Cr(III) in the lung and intestinal tract lining or upon cell entrance, Cr in biological material is most likely always trivalent, except shortly after exposure to Cr(VI) and in erythrocytes [22, 24] . The general population is mainly exposed to trivalent chromium Cr(III) through food and dietary supplements [22] . Other known sources of chromium are water, ambient air, and tobacco smoke [106] . Interestingly, tobacco smoke contains Cr(VI), thus co-exposure with other metals such as cadmium, lead, and nickel is possible [107] .
Chromium is mainly excreted through urine with a half-life of 15-41 h [108] while the half-life of whole Cr in blood is 13.9 days. Chromium both in urine and blood reflects relatively short-term exposure. Biomonitoring of Cr(VI) exposure is complicated by the high dietary intake of Cr(III) in the general population. The relative contribution of Cr(III) versus Cr(VI) to biomarkers of exposure is biospecimen-specific, with urine and serum Cr levels reflecting mostly Cr(III) exposure and whole blood Cr levels reflecting Cr(VI) exposure (Table 1) . Urinary Cr(VI) levels may be low after exposure to Cr(VI), as Cr(VI) is reduced to Cr(III) in vivo. Because Cr(VI), but not Cr(III), is taken up by erythrocytes, whole blood best reflects Cr(VI) exposure, and Cr(VI) has a half-life in blood of 25-35 days (Table 1 ) [24] . Since toenails have a slow growth rate, it has been estimated that toenail measurements represent exposures over last 3-12 months [25] . Overall, total biomarker levels are likely mostly reflecting Cr(III) in all the evaluated studies, especially studies using urine as biological matrix. Future epidemiologic studies, especially those based on whole blood, require chromium speciation to assess potentially adverse cardiovascular effects of Cr(VI).
Given the rapid reduction of Cr(VI) to Cr(III) and the inability of Cr(III) to enter cells, it is unlikely that the endothelium will be exposed to Cr(VI). Thus, there is no in vivo evidence linking exposure to chromium with atherosclerosis or endothelial function. Nonetheless, in experimental studies, Cr(VI) induced DNA damage due to reactive oxygen species caused by the reduction to Cr(III) [109] [110] [111] . Alternatively, experimental studies in rabbits describe an improvement of serum lipids using Cr(III) compounds [112, 113] .
In the systematic review, we identified five publications investigating the association between chromium and atherosclerotic disease that met the inclusion criteria (Table 3) . These studies were conducted in the USA [76] , Kingdom of Saudi Arabia [114] , Sweden [34] , Europe [115] , and Finland [116] . Three studies restricted to men only [76, 114, 115] , and a fourth study population included 92 % men [116] . Chromium exposure was measured in whole blood [34] , serum [114] , urine [114, 116] , and toenail [76, 115] . Cardiovascular disease endpoints were based on review of clinical and mortality records (coronary heart disease incidence [114, 115] and mortality [116] , and combined CVD endpoint including myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or stroke [76] ) and examination (presence of plaque in carotids [34] ). Chromium speciation was not conducted in any of these studies. Three studies [34, 76, 115] reported dose-response associations of urinary chromium with prevalent endpoints using quartile [76] and quintile [34, 115] categories. While the two studies [114, 116] using urine biomarkers divided urine chromium by urine creatinine, none of them conducted sensitivity analyses by showing effect estimates when no adjustment or only adjusting the regression model for creatinine.
All the studies included in the systematic review reported a trend toward inverse associations of chromium exposure and atherosclerotic disease (Table 3) , although it was statistically significant only in two studies [115, 116] . For descriptive purposes only, we performed a meta-analysis and estimated the combined relative risks from the five retrieved studies, obtaining a pooled relative risk that was marginally significant [0.89 (0.75, 1.05)] (Fig. 2) . Sequentially excluding each study did not change the pooled effect estimates (data not shown). Although analyses of bias are limited by the small number of studies, funnel plots and Egger's test indicated the potential for publication bias in studies evaluating Cr exposure (p = 0.104; p < 0.1 often considered significant in metaanalyses [74] ). We observed some heterogeneity between studies (I 2 = 48.0 %). One [76] and two [76, 115] studies reported adjustments for mercury and selenium, respectively. No study adjusted for lead and cadmium.
Tungsten
Tungsten is naturally occurring in rock and soil, and enters the environment from industrial output or naturally occurring contamination [23] . While the main source of tungsten exposure is occupational via inhalation of hard metal dust, the general population may be exposed through drinking water, food, or industrial releases into the environment [118, 119] . The elimination time of tungsten in most tissues, except bone, is 5 days (70 % of the dose) and 100 days (30 % of the dose). Consequently, urinary tungsten reflects recent exposure [23, 120] . Occupational inhalation of hard metal dust containing tungsten and cobalt causes asthma and fibrosis called hard metal disease [121, 122] . Although toxicological evidence regarding cardiovascular disease is sparse, in vivo studies suggest tungsten causes histological lesions in the heart [123] and can inactivate molybdenum enzymes by replacing molybdenum binding sites [124] . Tungsten likely causes oxidative stress [7, 11, 120, 125] and can modify cobalt toxicity [126] . There is little epidemiological evidence of tungsten exposure and cardiovascular disease in the general population, although tungsten exposure has been associated with elevated blood pressure [127] , excretion of reactive oxygen species [125] , and DNA methylation and hydroxymethylation [128] .
In the systematic review, we identified four publications investigating the association between tungsten and cardiovascular disease (Table 4 ). All studies were cross-sectional and conducted in the general US population in NHANES. Tungsten exposure was measured in urine only. Among the four retrieved studies, one cardiovascular endpoint was based on examination (peripheral arterial disease) [32] , while other endpoints were based on self-report of composite cardiovascular disease [31, 129•] , coronary heart failure, coronary heart disease, heart attack, and stroke [31, 129•] . The associations of elevated tungsten levels with composite cardiovascular disease [31, 129•] , peripheral arterial disease [32] , and stroke [129•] were statistically significant. The associations of tungsten with heart failure, coronary heart disease, heart attack, and stroke in one study [33] were in the positive direction but non-significant. One study reported dose-response associations using flexible splines [32] . All three studies took into account urine dilution by adjusting the regression models by urine creatinine. Two studies adjusted for molybdenum and cobalt [33, 129•] . Only one study also adjusted for cadmium and lead [33] .
Other Metals
Other non-essential metals are also of potential cardiovascular concern. Barium sulfide is produced from mineral barite, and it is used mainly in oil and gas drilling industry and in the manufacture of alloys, glass, cement, ceramics, electronics, radiopaque contrast, sugar refining, and as pigment. The general population is exposed to barium from gasoline [130] , soil, air, water [131] , and food, especially nuts [132] . Chronic effects of barium on the cardiovascular system are unclear. An occupational study on barium workers, who were exposed to other chemicals, found higher incidence of elevated blood pressure in the barium-exposed group [133] . Studies in populations exposed through drinking water, however, found no significant differences in blood pressure, heart disease, stroke, kidney disease, or lung disease [134, 135] . Different studies have measured barium concentration in hair, urine, and blood samples. Barium is mainly excreted through feces (91 %), sweat (6 %), and urine (3 %) [136] . The pattern of total excretion fits a three-component exponential function with biological half-times of 3.6, 34.2, and 1033 days, respectively [137] .
Nickel is a natural element present in sulfide or oxide ores, and it is used in steel and alloy industries, batteries, and chemical catalysis. Nickel is widely used in coins, jewelry, watches, buttons, orthodontic and orthopedic uses, and stents. The general population is exposed to nickel from combustion of fossil fuel and pollution through air, soil, and water [138] , food (cacao, nuts [139] ), and tobacco smoking [140] . Nickel is an established carcinogen in occupational settings (respiratory cancers), especially insoluble nickel sulfide and nickel oxide [27, 141, 142] . Other chronic health effects associated to nickel include rhinitis, sinusitis, nasal septum perforations, asthma, skin allergies, and reproductive effects [27] . Although biomarkers of nickel exposure are not well validated, nickel has been measured in whole blood, serum, plasma, and urine [27] . It is well established that nickel is rapidly excreted Only mean Cr levels for cases and controls were originally reported; we derived the IQR, RR, and 95 % CI via the linear discrimination method [117] through urine with a half-life of 20 to 27 h [143] , with salivary and sweat excretion being secondary [144] . Uranium is used in energy production, glass tinting agents, ceramic glazes, gyroscope wheels, chemical catalysts, shields for high-intensity radioactive sources, x-ray tube targets, and military munitions [30] . Uranium is ubiquitous in the environment; for that reason, the general population is exposed to uranium from soil, air, water, and food [29] . Although uranium is both a chemical and a radioactive material, it has been determined that its adverse health effects are primarily a result of its chemical rather than radiological toxicity [29] . Chemical exposure in humans has been related with hepatitis, lung toxicity, and renal disease caused by oxidative stress [145, 146] , and these effects have not been demonstrated in radiological studies [147] . Among uranium miners, the causal relationship between exposure to radon progeny and lung cancer is well established, although the carcinogenicity of uranium itself remains unknown [29] . Uranium in body fluids generally exists as a uranyl ion UO 2 complex. It accumulates in tissues (especially bone) or it is excreted quickly by urine, with a two-phase model in kidneys from 1 to 6 days (99 %) to 1500 days (100 %) [30] .
Experimental evidence indicating a potential role in atherogenesis of these metals is scarce. The barium ion is a physiological antagonist of potassium, and it is related to acute effects in radiopaque barium sulfate intoxications with smooth, skeletomuscular, and cardiac symptoms like areflexia and heart fibrillation [148] . One study in rat has assessed the effect induced by chronic ingestion of uranium in reducing the activity of cholesterol 7 alpha-hydroxylase (CYP7A1) [149] , which is involved in lipid metabolism. In vivo evidence on the potential role of these metals in atherosclerosis is needed.
Our systematic review identified very few articles that met the inclusion criteria on the association of these other metals with cardiovascular atherosclerotic disease ( Table 5 , Supplemental File 3). For each of these metals, we only identified one publication investigating the association with atherosclerotic cardiovascular disease: barium and peripheral arterial disease [32] , nickel and carotid atherosclerosis [34] , and uranium and the prevalence of cardiovascular endpoints including coronary heart disease, stroke, and heart failure ( Table 5 ). These studies were conducted in the USA [32, 33] and Sweden [34] . Exposure was measured in urine only [32, 33] or whole blood only [34] . Cardiovascular endpoints were assessed by physical examination in two studies (one measuring peripheral arterial disease with ankle-brachial index [32] and one measuring carotid atherosclerosis by intima-media thickness and plaque presence with ultrasounds [34] ) and by self-report in one study [33] . For barium, there was a trend toward inverse association with peripheral arterial disease, although it was not significant [32] . For nickel and uranium, the evaluated studies mostly showed a trend toward increased cardiovascular risk with increasing levels of exposure [33, 34] , which was statistically significant for heart failure and heart attack. Two studies adjusted for age, sex, and smoking, but failed to adjust for traditional cardiovascular risk factors.
General Discussion and Needs for Future Epidemiologic Research
Few studies have evaluated the association between other metals beyond lead and cadmium, or the metalloid arsenic, Fig. 2 Relative risks (RRs) for cardiovascular disease endpoints for a given change in chromium level. Squares and diamonds represent effect estimates and are proportional to the inverse of the variance of the log odds ratios, and lines represent 95 % CIs. a Niskanen et al. only reported mean levels of urinary Cr among cases and controls; we derived RR and 95 % CI via the linear discrimination method [117] . NR not reported, CHD coronary heart disease, MI myocardial infarction. Total N was reported where number of cases/non-cases was not available. Pooled estimates within and across studies were pooled via inverse-variance weighted random effects with cardiovascular disease development including information on age, sex, and smoking status. The metals for which we found at least two or more studies included antimony, tungsten, and chromium. For the association of antimony and tungsten exposures with different atherosclerotic endpoints, all the studies were conducted in NHANES, a representative sample of the general US population. Although these studies found an increased risk of CVD-related outcomes with increased antimony and tungsten concentrations, more studies in other populations are needed to evaluate the consistency of the findings. For chromium, epidemiologic studies in distinct populations consistently found an inverse association between chromium biomarkers including serum, urine, whole blood, and toenail, and incident and prevalent atherosclerotic disease. A graphical display analysis, however, indicates there is possibility of risk of publication bias. This finding highlights the importance of publishing all studies, including null studies, not only for chromium but also for other metals. Additional research is thus needed to confirm the relationship between chromium and cardiovascular disease, including the shape of the dose-response, and, most importantly, to distinguish if the association is different by chromium species. For other environmental metals, the small number of studies did not allow us to recognize any type of patterns in their associations with atherosclerotic disease, although the association for uranium was suggestive of increased risk. These epidemiologic associations of a potential increased risk of CVD for antimony, tungsten, and uranium are also supported by a few experimental studies specifically conducted for those metals. Additional experimental research is needed to better understand the potential mechanisms, the dose-response, and the impact of different routes of administration. These experimental studies are critical to facilitate the interpretation and the conduction of human research. While the small number of studies limits the conclusion of this review, the evidence accrued so far supports the importance of environmental metals as cardiovascular risk factors, with different directions of the association for chromium vs. the other metals. Table 1 summarizes the characteristics and interpretation of the metal biomarkers relevant for this systematic review. Spot urine biomarkers were the most commonly used biospecimen among the reviewed studies. Limitations of urine biomarkers include within-individual variability in urinary metal excretion and the need to adjust or correct for urine dilution [32] . Variation associated with the laboratory technique for metal determination (typically inductively coupled plasma-mass spectrometry), including relatively high limits of detection that results in a large proportion of the study population with unobserved metal concentrations, also introduces measurement error. Only four studies [32, [114] [115] [116] reported the inter-assay coefficient of variations of the laboratory method, which typically should fall below the 10 % threshold. Only five studies [32, 33, 35••, 115, 129•] reported the percent of undetectable values, the limit of detection for the specific metals, or the methods to handle undetectable values. Traditional approaches to handle left-censored data, such as replacing concentrations below the limit of detection by the limit of detection divided by two or the square root of two, may induce bias when more than 10-20 % of the study population display undetectable values [150] . Recently developed imputation approaches based on Markov Chain Monte Carlo predictive models have been applied with the objective to flexibly incorporate measurement error and left truncation, improve the estimation of dose-responses, and increase sample size when values are missing completely at random [151, 152] . Typically, non-differential measurement error related to physiological urinary metal and creatinine excretion and artifactual variation could introduce conservative bias toward the null. Additionally, given the relatively short half-lives of most urinary metals, the biomarkers may not reflect longterm exposures (Table 1) , although short half-life biomarkers can reflect chronic exposure if exposure is constant over time.
A limitation of the retrieved studies was the substantial heterogeneity in the adjustment for traditional cardiovascular risk factors. We included adjustment for sex, age, and smoking status as required inclusion criteria because they are major confounders of the association between metal exposure and cardiovascular disease, and smoking is a major source of metal exposure [152, 153] . Only one [34] study reported results stratified by age subgroups, two studies [34, 129•] reported results stratified by sex, and no studies reported results stratified by smoking status. Conducting stratified analysis can be difficult in studies with small sample sizes, as was common in the studies included in this review (median sample size 1247). Most of the studies adjusted for diabetes, hypertension, and dyslipidemia. An important issue is the adjustment for renal function, as some of the reported metals such as chromium [153] [154] [155] , antimony [156] , and uranium [157] are nephrotoxic and could, thus, be mediators of the association of metals and cardiovascular disease. Although there is discussion on the adequacy of urine creatinine to correct for urine dilution for metal biomarkers, adjustment for specific gravity cannot be interpreted in the presence of albuminuria, which also limits the value of specific gravity to account for urine dilution in the presence of kidney damage [158] .
Only one prospective study, a nested case-control study conducted for chromium [76] , allowed the assessment of temporality. The study found a prospective inverse association of baseline chromium with coronary heart disease incidence collected through 10 years of follow-up. This prospective association was directionally consistent with cross-sectional [34, 76] and case-control [114, 115] studies. Regarding the doseresponse, some studies used flexible approaches (i.e., quantile categories or non-parametric splines) mostly showing approximately monotonic relationships of chromium [34, 76, 115] , antimony [32, 35••] , and tungsten [32] with cardiovascular disease.
Future prospective studies with sufficient repeated measurements over time, which can enable the evaluation of cardiovascular risk by changes in environmental metals, are needed. Another interesting area of future research is the role of joint exposures in atherosclerosis. It is important to evaluate mixtures of metals as metals co-occur together [159, 160] . While several of the retrieved studies adjusted the regression models for other metals, statistical methods to comprehensively tackle mixtures of compounds are needed.
In addition to primary prevention interventions to reduce exposure to atherogenic metals in general populations, future mechanistic and human experimental research is needed to clarify the effect of removing potentially atherogenic metal stores from the body via edetate disodium chelation treatment in the prevention of recurrent cardiovascular disease [5••] . For chromium, further experimental evidence is needed to clarify the potential mechanism for improved glycemic control, and further epidemiological studies using more precise biomarkers of Cr(III) and Cr(VI) exposure are needed to clarify the species-specific association with cardiovascular disease.
Conclusion
The accumulated evidence is consistent with a role of environmental metals in atherosclerotic disease. However, for all the environmental metals evaluated, including chromium, we concluded that the current evidence is "insufficient" to support causality given the small number of studies, the heterogeneity in potential residual confounding of the associations by traditional cardiovascular risk factors and metal co-exposures, and the few number of prospective studies. For chromium, despite consistent inverse associations among published studies, the potential mechanisms are unclear, and we cannot discard possible publication bias. Important questions include the need for larger and prospective studies, the relevance of issues related with adjustment for urine dilution when using urinary biomarkers, and the systematic evaluation of the dose-response relationships. Cardiovascular disease will remain the main cause of burden of disease worldwide in the next decades [161] . Given the potential associations between metal exposure and cardiovascular disease as well as the paucity of experimental literature on metal-induced cardiotoxicity, more experimental research is needed to determine the potential mechanism of metal-induced atherosclerosis.
